Treatment exit options for non-infectious uveitis registry: participant characteristics at 3 years : inflammation : clinical science
Purpose The Treatment exit Options For non-infectious Uveitis (TOFU) registry documents disease courses for non-anterior non-infectious uveitis entities with and without treatment to generate more evidence for clinical management recommendations including treatment exit strategies. In this article,...
Gespeichert in:
| Hauptverfasser: | , , , , , , , , , , , , |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
2024
|
| In: |
British journal of ophthalmology
Year: 2025, Jahrgang: 109, Heft: 1, Pages: 27-33 |
| ISSN: | 1468-2079 |
| DOI: | 10.1136/bjo-2023-324927 |
| Online-Zugang: | Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1136/bjo-2023-324927 Verlag, lizenzpflichtig, Volltext: http://bjo.bmj.com/content/early/2024/06/10/bjo-2023-324927 
|
| Verfasserangaben: | David Julian Fink, Jennifer Dell, Carsten Heinz, Maximilian WM Wintergerst, Tobias Höller, Moritz Berger, Matthias Schmid, Karl Thomas Boden, Uwe Pleyer, Herbert Reitsamer, Christoph ME Deuter, Tibor K Lohmann, Robert P Finger, TOFU Registry Study Group |
MARC
| LEADER | 00000caa a22000002c 4500 | ||
|---|---|---|---|
| 001 | 1909465313 | ||
| 003 | DE-627 | ||
| 005 | 20251128120119.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 241125s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1136/bjo-2023-324927 |2 doi | |
| 035 | |a (DE-627)1909465313 | ||
| 035 | |a (DE-599)KXP1909465313 | ||
| 035 | |a (OCoLC)1475648038 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Fink, David |d 1991- |e VerfasserIn |0 (DE-588)1308513550 |0 (DE-627)1869122569 |4 aut | |
| 245 | 1 | 0 | |a Treatment exit options for non-infectious uveitis registry |b participant characteristics at 3 years : inflammation : clinical science |c David Julian Fink, Jennifer Dell, Carsten Heinz, Maximilian WM Wintergerst, Tobias Höller, Moritz Berger, Matthias Schmid, Karl Thomas Boden, Uwe Pleyer, Herbert Reitsamer, Christoph ME Deuter, Tibor K Lohmann, Robert P Finger, TOFU Registry Study Group |
| 264 | 1 | |c 2024 | |
| 300 | |a 7 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Erstmals veröffentlicht: 10. Juni 2024 | ||
| 500 | |a Gesehen am 25.11.2024 | ||
| 520 | |a Purpose The Treatment exit Options For non-infectious Uveitis (TOFU) registry documents disease courses for non-anterior non-infectious uveitis entities with and without treatment to generate more evidence for clinical management recommendations including treatment exit strategies. In this article, we present the participants’ baseline characteristics after the first 3 years. - Methods TOFU is an observational, prospective registry and recruits patients ≥18 years of age with non-anterior non-infectious uveitis with or without a history of previous disease-modifying antirheumatic drugs (DMARDs) treatment. The data are collected in the electronic data capture software REDCap and include ophthalmological and general medical history as well as clinical findings. - Results Between 24.10.2019 and 27.12.2022, 628 patients were enrolled at 25 clinical sites in Germany and Austria. Patients with intermediate uveitis were most frequently included (n=252; 40.1%) followed by posterior uveitis (181; 28.8%), panuveitis (n=154; 24.5%) and retinal vasculitis (n=41, 6.5%). At baseline, 39.6% were treated with systemic corticosteroids, 22.3% with conventional synthetic (cs) DMARDs, 20.5% with biological (b) DMARDs and 3.6% with other systemic treatments. Average best corrected visual acuity (BCVA) was 0.69 decimal. Patients with panuveitis had the worst BCVA with 0.63 decimal. Overall, only 8 patients (1.3%) suffered from severe visual impairment. - Conclusions Less than half of participants required DMARD treatment at baseline, with csDMARDs used more frequently than bDMARDs. The presence of severe visual impairment was low, mostly affecting patients with panuveitis. These findings are in line with comparable monocentric cross-sectional studies of tertiary uveitis centres in Germany and will allow us to generate generalisable evidence in TOFU. | ||
| 650 | 4 | |a Immunology | |
| 650 | 4 | |a Inflammation | |
| 650 | 4 | |a Treatment Medical | |
| 700 | 1 | |a Dell, Jennifer |e VerfasserIn |4 aut | |
| 700 | 1 | |a Heinz, Carsten |e VerfasserIn |4 aut | |
| 700 | 1 | |a Wintergerst, Maximilian W. M. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Höller, Tobias |e VerfasserIn |4 aut | |
| 700 | 1 | |a Berger, Moritz |e VerfasserIn |4 aut | |
| 700 | 1 | |a Schmid, Matthias |e VerfasserIn |4 aut | |
| 700 | 1 | |a Boden, Karl Thomas |e VerfasserIn |4 aut | |
| 700 | 1 | |a Pleyer, Uwe |e VerfasserIn |4 aut | |
| 700 | 1 | |a Reitsamer, Herbert |e VerfasserIn |4 aut | |
| 700 | 1 | |a Deuter, Christoph M. E. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Lohmann, Tibor K. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Finger, Robert P. |d 1979- |e VerfasserIn |0 (DE-588)133279049 |0 (DE-627)539656488 |0 (DE-576)287511855 |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t British journal of ophthalmology |d London : BMJ Publ. Group, 1917 |g 109(2025), 1, Seite 27-33 |h Online-Ressource |w (DE-627)300594267 |w (DE-600)1482974-5 |w (DE-576)078993598 |x 1468-2079 |7 nnas |a Treatment exit options for non-infectious uveitis registry participant characteristics at 3 years : inflammation : clinical science |
| 773 | 1 | 8 | |g volume:109 |g year:2025 |g number:1 |g pages:27-33 |g extent:7 |a Treatment exit options for non-infectious uveitis registry participant characteristics at 3 years : inflammation : clinical science |
| 856 | 4 | 0 | |u https://doi.org/10.1136/bjo-2023-324927 |x Verlag |x Resolving-System |z lizenzpflichtig |3 Volltext |
| 856 | 4 | 0 | |u http://bjo.bmj.com/content/early/2024/06/10/bjo-2023-324927 |x Verlag |z lizenzpflichtig |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20241125 | ||
| 993 | |a Article | ||
| 994 | |a 2024 | ||
| 998 | |g 133279049 |a Finger, Robert P. |m 133279049:Finger, Robert P. |d 60000 |d 61700 |e 60000PF133279049 |e 61700PF133279049 |k 0/60000/ |k 1/60000/61700/ |p 13 |y j | ||
| 999 | |a KXP-PPN1909465313 |e 4622152053 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"relHost":[{"recId":"300594267","pubHistory":["1.1917 -"],"note":["Gesehen am 03.12.12"],"origin":[{"dateIssuedKey":"1917","publisher":"BMJ Publ. Group","dateIssuedDisp":"1917-","publisherPlace":"London"}],"id":{"issn":["1468-2079"],"zdb":["1482974-5"],"eki":["300594267"]},"language":["eng"],"name":{"displayForm":["Institute of Ophthalmology. Ed. Sir Stewart Duke-Elder [u.a.]"]},"titleAlt":[{"title":"BJO"}],"corporate":[{"role":"isb","display":"University of London"}],"disp":"Treatment exit options for non-infectious uveitis registry participant characteristics at 3 years : inflammation : clinical scienceBritish journal of ophthalmology","physDesc":[{"extent":"Online-Ressource"}],"title":[{"subtitle":"BJO","title":"British journal of ophthalmology","title_sort":"British journal of ophthalmology"}],"part":{"year":"2025","pages":"27-33","text":"109(2025), 1, Seite 27-33","volume":"109","extent":"7","issue":"1"},"type":{"bibl":"periodical","media":"Online-Ressource"}}],"recId":"1909465313","note":["Erstmals veröffentlicht: 10. Juni 2024","Gesehen am 25.11.2024"],"origin":[{"dateIssuedDisp":"2024","dateIssuedKey":"2024"}],"id":{"eki":["1909465313"],"doi":["10.1136/bjo-2023-324927"]},"physDesc":[{"extent":"7 S."}],"person":[{"display":"Fink, David","given":"David","role":"aut","family":"Fink"},{"role":"aut","display":"Dell, Jennifer","given":"Jennifer","family":"Dell"},{"family":"Heinz","given":"Carsten","display":"Heinz, Carsten","role":"aut"},{"role":"aut","given":"Maximilian W. M.","display":"Wintergerst, Maximilian W. M.","family":"Wintergerst"},{"role":"aut","display":"Höller, Tobias","given":"Tobias","family":"Höller"},{"role":"aut","display":"Berger, Moritz","given":"Moritz","family":"Berger"},{"family":"Schmid","given":"Matthias","display":"Schmid, Matthias","role":"aut"},{"family":"Boden","given":"Karl Thomas","display":"Boden, Karl Thomas","role":"aut"},{"family":"Pleyer","role":"aut","display":"Pleyer, Uwe","given":"Uwe"},{"role":"aut","display":"Reitsamer, Herbert","given":"Herbert","family":"Reitsamer"},{"given":"Christoph M. E.","display":"Deuter, Christoph M. E.","role":"aut","family":"Deuter"},{"family":"Lohmann","display":"Lohmann, Tibor K.","given":"Tibor K.","role":"aut"},{"display":"Finger, Robert P.","given":"Robert P.","role":"aut","family":"Finger"}],"title":[{"subtitle":"participant characteristics at 3 years : inflammation : clinical science","title_sort":"Treatment exit options for non-infectious uveitis registry","title":"Treatment exit options for non-infectious uveitis registry"}],"type":{"media":"Online-Ressource","bibl":"article-journal"},"name":{"displayForm":["David Julian Fink, Jennifer Dell, Carsten Heinz, Maximilian WM Wintergerst, Tobias Höller, Moritz Berger, Matthias Schmid, Karl Thomas Boden, Uwe Pleyer, Herbert Reitsamer, Christoph ME Deuter, Tibor K Lohmann, Robert P Finger, TOFU Registry Study Group"]},"language":["eng"]} | ||
| SRT | |a FINKDAVIDDTREATMENTE2024 | ||